Fotios Barkas
@fotiosbarkas.bsky.social
57 followers 130 following 26 posts
Assistant Professor of Internal Medicine @ University of Ioannina | Research Fellow @ ICCP & ICTU, Faculty of Medicine, Imperial College London, UK | EAS Young Fellow & SoMe Ambassador | FN SCOPE | Lipidology, Obesity Expert
Posts Media Videos Starter Packs
fotiosbarkas.bsky.social
🚀 Big win for #ASCVD Prevention!
The VESALIUS-CV Phase 3 trial fullfilled its primary endpoints: #evolocumab significantly reduced CVD events in high-risk patients without prior AMI or stroke. 💥💓
This is a major leap forward for primary prevention!
zurl.co/SPJSp

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha®...
www.prnewswire.com
fotiosbarkas.bsky.social
👏 Well done Nikolaos - Gavriil Kolios, who is one of my PhD Students, and the rest of the team George Ntaios H Milionis #Stroke #ACS #LipidLowering #cholesterol
fotiosbarkas.bsky.social
👌 We know what to do after acute #coronary events

🤔 But what about stroke 🧠, the leading cause of #disability worldwide?

🧐 What’s the evidence 📚, which drugs 💊, and how low to go 📉?

Enjoy 👇 www.thieme-connect.com/products/ejo...
fotiosbarkas.bsky.social
#EASYOUNGFELLOWS #EAS
#SGLT2i #Atherosclerosis #Diabetes #CVPrevention
fotiosbarkas.bsky.social
🚨 Just out in the American Journal of Preventive Cardiology!
Our latest review on the atheroprotective power of #SGLT2 inhibitors 💥
From 🧠 #stroke to #CAD & #PAD — SGLT2i are changing the game in #CVD prevention!
Read it here!
doi.org/10.1016/j.aj...
fotiosbarkas.bsky.social
📖 Read the full paper here:
🔗 www.jacc.org/doi/10.1016/...

👏 Huge credit to all INTERASPIRE Investigators for this global contribution to cardiovascular prevention!

#LipoproteinA #Lp_a #CVDPrevention #CardioTwitter #Lipidology #JACC #GlobalHealth
fotiosbarkas.bsky.social
4️⃣ Most patients with high Lp(a) also had poorly controlled traditional risk factors.

📈 In regions lacking access to novel therapies, risk factor management must be improved several fold to offset Lp(a)-related residual risk.
fotiosbarkas.bsky.social
3️⃣ Traditional lipids don’t predict Lp(a).
LDL-C, non–HDL-C, and ApoB did not correlate with Lp(a) across most of its range.

✅ Bottom line: Measure Lp(a) directly—don’t rely on traditional lipids.
fotiosbarkas.bsky.social
2️⃣ Eligibility for emerging Lp(a)-lowering therapies:

▪️ 6.2% at ≥200 nmol/L
▪️ 13.0% at ≥150 nmol/L

⚠️ Marked variation across WHO regions and even between countries within the same region.
fotiosbarkas.bsky.social
1️⃣ Median Lp(a): 32 nmol/L
👉 82.4% of patients were below the 125 nmol/L threshold typically linked to increased ASCVD risk.
🧠 Suggests that Lp(a)’s contribution to CHD may be more complex than previously assumed.
fotiosbarkas.bsky.social
🚨 Recently in @jaccjournals.bsky.social Key findings from the INTERASPIRE study on Lp(a) in 3,928 CHD patients across 13 countries 🌍

A 🧵 on what we found & what it means for future Lp(a)-lowering therapies:
fotiosbarkas.bsky.social
🔜 See you next year—and don’t forget:
📍 December 2025 in Athens: Panhellenic Congress of HAS Working Groups
📍 May 2026 in Athens: EAS Congress
fotiosbarkas.bsky.social
🎓 And just like that, our Summer School has come to an end!
A heartfelt THANK YOU to all our amazing speakers and the engaged scholars who enriched the sessions with their questions and insights! 🙌
What a truly fruitful and inspiring experience!

#Dyslipidemia #SummerSchool #HAS2025 #EAS #Lipids
fotiosbarkas.bsky.social
🎉 The HAS Summer School has just kicked off!!
🧑‍🎓Time to dive deep into #lipoprotein metabolism with Prof Alexandros Tselepis and the epidemiology of secondary #dyslipidemias with Prof Demosthenes Panagiotakos!

#HellenicAtherosclerosisSociety #HAS2025
fotiosbarkas.bsky.social
us02web.zoom.us/webinar/regi...

#Lipids #Hypertriglyceridemia #triglycerides #CVD #cardiovasculardisease
fotiosbarkas.bsky.social
🚨 Don’t miss this must-attend webinar!
🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection
🎙️ Keynote: Prof. Daniel Gaudet
📅 Wednesday, June 4, 2025
🕕 17:00 CET
💻 Online | Registration required
🔗 Reserve your spot now!
Registration link below!
fotiosbarkas.bsky.social
📍See you in Athens this December & at #EASCongress2026 in May!
#atherosclerosis #HAS #CVD #EAS2025 #Cyprus #Greece
fotiosbarkas.bsky.social
🎉 The 1st Pan-Cypriot Atherosclerosis Congress 🇨🇾 concluded with great success!
A flawlessly organized event with high-level scientific content and warm hospitality.
Representing the Hellenic Atherosclerosis Society 🇬🇷, we extend a big thank you to our colleagues in Cyprus!
fotiosbarkas.bsky.social
A deep dive into secondary causes of #dyslipidemia, interactive sessions & the latest in #CardiovascularPrevention in a closed meeting with chosen scholars from #Greece and #Cyprus!💡

#Atherosclerosis #Syros2025 #MedicalEducation #Lipids #SummerSchool #ConferreMedConnect
fotiosbarkas.bsky.social
🚨 Coming up: 18th Summer School of the Hellenic Atherosclerosis Society
🗓 June 6–7, 2025 | 📍Syros, Greece 🇬🇷
fotiosbarkas.bsky.social
How you can get a grant?
Tips from the best! Judith Sluimer Keith Channon
New #AtheroTalk podcast now available!
Live from #EASCONGRESS2025!!
ENJOY! 👇👇👇👇👇👇👇👇👇👇🤔
open.spotify.com/episode/4ngq...
E14 LIVE from EAS 2025: Behind the Grant Application with Judith Sluimer & Keith Channon
AtheroTalk · Episode
open.spotify.com
fotiosbarkas.bsky.social
What does EAS Young Fellows Programm mean?? It means SCIENCE, PASSION, FRIENDSHIP & a touch of ART — all in one squad! Loving the energy at #EASCongress2025 #EASYoungFellows #MyEAS2025 #AtheroTalk
fotiosbarkas.bsky.social
We are waiting for you at the EAS Stage!!
Social media and the physician: What can we harness?
A powerful reminder of the digital tools at our fingertips to educate, connect, and inspire!
#EAS2025 #EASCongress2025 #EASSoMe
fotiosbarkas.bsky.social
We’ve just kicked off the E-HEALTH, AI AND BIG DATA workshop at #EAS2025 — where cutting-edge digital health meets clinical impact!

#EASCongress2025 #EASSoMe